Loading...

APUS APIMEDS PHARMACEUTICALS US INC Company Mergers 8-K Filing

PMDS

PS

APIMEDS PHARMACEUTICALS US INC

(APUS)

2026 8-K

New CEO Appointment

Settlement Agreement

Delisting Notice

Filings Delay Notification

Stockholder Consent Nullified

Board Changes Invalidated

Board Restructuring

Stock Split Announcement

Director Resignations

Merger Amendment Notice

Merger Agreement

CEO Salary Increase

Bylaw Amendment

Investor Meetings

Debt Restructuring

External Links:

On April 24, 2026, Apimeds Pharmaceuticals US, Inc. entered into a Settlement Agreement resolving disputes related to a merger, which includes a $4 million working capital contribution and the retention of certain program rights by a partner.

AI Assistant

APIMEDS PHARMACEUTICALS US INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.